Login to Your Account

Arsanis’s Series B Adds $20M to Move Staph Drug into Clinic

By Nuala Moran
Staff Writer

Wednesday, September 11, 2013

LONDON – Arsanis Inc. has raised $20 million in Series B funding that will enable the Austro-American company to take its lead monoclonal antibody product, ASN-100, through Phase I/IIa development in the treatment of severe, hospital-acquired Staphylococcus aureus infections.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription